Amgen has agreed to acquire Dark Blue Therapeutics in a deal valued at up to $840 million, as the biopharmaceutical company continues to build out its early-stage oncology pipeline. The specific breakdown of the upfront payment alongside development and regulatory milestones was not disclosed in the press release.
Organoids are reshaping cancer R&D by providing more accurate, patient-relevant models than classical methods. By bridging the gap between preclinical and early clinical stages, they enable patient-centric target validation, drug discovery, and therapeutic development, representing a significant step toward truly precision oncology
Lyon-based Ventuno Biotech secures fresh backing to accelerate its preclinical pipeline of first-in-class immuno-oncology assets.
Pilatus Biosciences AG, a Swiss biotechnology company headquartered in Epalinges with operations in the United States and South Korea, has entered into a clinical trial collaboration with Roche AG. As part of the agreement, Roche will provide its PD-L1 immune checkpoint inhibitor atezolizumab for use in a Phase I study evaluating the combination of atezolizumab with Pilatus’s investigational CD36 inhibitor, PLT012, in patients with hepatocellular carcinoma (HCC).
Krakow-based oncology specialist Ryvu Therapeutics zoo today announced a strategic reorganisation that will extend Ryvu’s cash runway to H2/2026 to focus on accelerating three ongoing RVU120 clinical programmes, and early pipeline small molecule and ADC assets to key data inflection points.
The Strasbourg-based biotech company Transgene and the Berlin-based CDMO ProBioGen have entered into a licensing agreement to collaboratively advance the development of individualised cancer vaccines.
A Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: AstraZeneca’s share price dropped 5% following the announcement.
Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.
Oss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.
Pierre Fabre Médicament SAS has entered into an Asset Purchase Agreement (APA) over pan-RAF programs developed by Kinnate Biopharma Inc.
freshidea / Adobe Stock
Pilatus Biosciences
Ryvu Therapeutics zoo
ProBioGen
AstraZeneca